StockNews.AI
TELA
StockNews.AI
152 days

TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results

1. TELA reported $69.3 million revenue for 2024, 19% growth year-over-year. 2. OviTex unit sales increased by 33% reflecting strong product demand. 3. 2025 revenue forecast between $85.0 million and $88.0 million indicates growth. 4. Cost-cutting measures in 2024 reduced operating expenses significantly. 5. Despite challenges, CEO expresses optimism about market opportunities and profitability.

Earnings
-37.18%Current Return
VS
-0.31%S&P 500
$2.3403/20 04:14 PM EDTEvent Start
$1.4703/21 10:31 PM EDTLatest Updated
15m saved
Insight
Article

FAQ

Why Bullish?

Revenue growth and product demand suggest favorable market conditions. Historical comparisons show positive reactions to such growth.

How important is it?

Financial growth, product adoption, and future revenue guidance are critical for investor perception.

Why Long Term?

Sustained product demand and strategic shifts indicate potential long-lasting positive effects on revenue.

Related Companies

AXNXCOOAPLS
March 20, 2025 16:05 ET  | Source: TELA Bio, Inc. MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, respectively;Drove expanded adoption of Company products in hernia procedures with the launch of OviTex IHR Reinforced Tissue Matrix, specifically engineered for laparoscopic and robotic-assisted inguinal hernia repair, selling over 1,200 units in 2024 from its launch in mid-April 2024;Implemented cost reduction efforts with a meaningful sequential step down in OpEx from the third to the fourth quarter, with the goal to offset additional investments into our commercial organization and keep 2025 OpEx remaining at the same level as in 2024; andProvided full year 2025 revenue guidance of $85.0 million to $88.0 million, representing 23% to 27% year-over-year growth. “Our team delivered 19% revenue growth in 2024, and we saw multiple record-high sales months throughout the year. Our fourth quarter results fell short of our expectations due to a confluence of disruptions, some of which we believe are transient and others that have already been redressed. Despite these challenges, the overall opportunity for substantial value creation from current levels remains intact,” said Antony Koblish, co-founder, President, and Chief Executive Officer of TELA Bio. “We believe our OviTex and OviTex PRS products remain well-positioned to benefit from several long-term tailwinds, most significantly an ongoing shift in the hernia repair market away from permanent synthetic mesh and increasing interest among surgeons in device alternatives to cadaveric tissue in plastic and reconstructive surgery. We are optimistic about TELA’s outlook moving forward and believe we have taken necessary steps to drive additional market share capture in our primary indications, restore topline growth more consistent with our historical precedent, and continue our steady path towards profitability.” Fourth Quarter 2024 Financial Results Revenue was $17.6 million in the fourth quarter of 2024, an increase of 4% compared to the same period in 2023. The increase was due to an increase in unit sales of our products resulting from the addition of new customers and growing international sales. This growth was partially offset by a decrease in average selling prices caused by product mix as the share of smaller-sized units increased following the introduction of robotically compatible OviTex IHR and our increased focus in growing market share in high-volume minimally invasive and robotic procedures. Gross profit was $11.2 million in the fourth quarter of 2024, or 64% of revenue, compared to $11.6 million, or 68% of revenue, in the same period in 2023. The decrease in gross margin was primarily due to higher expense recognized for excess and obsolete inventory adjustments due to the introduction of newer generation products. Operating expenses were $19.6 million in the fourth quarter of 2024, compared to $23.9 million in the same period in 2023. The decrease was due to lower compensation costs resulting from efficiency efforts initiated in the third quarter of 2024, as well as decreased travel, consulting and professional fees. Loss from operations was $8.4 million in the fourth quarter of 2024, compared to a loss from operations of $12.3 million in the same period in 2023. Net loss was $9.2 million in the fourth quarter of 2024, compared to a net loss of $12.9 million in the same period in 2023. Full Year 2024 Financial Results Revenue was $69.3 million for the full year 2024, an increase of 19% compared to the same period in 2023. The increase was primarily due to an increase in unit sales of our products resulting from the addition of new customers and growing international sales. This growth was partially offset by a decrease in average selling prices caused by product mix as the share of smaller-sized units increased following the introduction of robotically compatible OviTex IHR and our increased focus in growing market share in high-volume minimally invasive and robotic procedures. Gross profit was $46.5 million in the full year 2024, or 67% of revenue, compared to $40.1 million, or 69% of revenue, in 2023. The decrease in gross margin was primarily due to higher expense recognized for excess and obsolete inventory adjustments due to the introduction of newer generation products. Operating expenses were $88.2 million in the full year 2024, compared to $84.2 million in 2023. The increase was due to higher compensation costs and employee-related expenses primarily from commissions on an increased revenue base and severance costs, as well as increased travel, consulting and additional selling related expenses related to product sampling and meeting expenses. Loss from operations was $34.1 million in the full year 2024, compared to a loss from operations of $44.1 million in 2023. Net loss was $37.8 million in the full year 2024, compared to a net loss of $46.7 million in 2023. Cash and cash equivalents on December 31, 2024 totaled $52.7 million. 2025 Financial Guidance Full year 2025 revenue is projected to range from $85.0 million to $88.0 million, representing growth of 23% to 27% over full year 2024.First quarter 2025 revenue is projected to range from $17.0 million to $18.0 million, representing growth of 2% to 8% over the first quarter of 2024.2025 operating expenses are expected to be flat to 2024. Conference Call TELA Bio will host a conference call at 4:30 p.m. Eastern Time on Thursday, March 20, 2025 to discuss its fourth quarter and full year 2024 financial results. Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A replay of the webcast can be accessed via the Events & Presentations page of the investor section of TELA Bio's website. About TELA Bio, Inc. TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com. Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. Such forward-looking statements include statements relating to our expected revenue and revenue growth for the full year 2025 and reduction in operating expenses throughout the full year 2025 compared to prior periods. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: the impact to our business from macroeconomic conditions, including recessionary concerns, banking instability, increasing market interest rates, monetary policy changes, changes in trade policies, including tariffs, and inflationary pressures, potentially impacting our ability to market our products; demand for our products related to changes in volumes or frequency of surgical procedures, including due to outbreak of illness or disease, cybersecurity events impacting hospital operations, labor and hospital staffing shortages, supply chain disruptions to critical surgical and hospital supplies, pricing pressures or any other applicable adverse healthcare economic factors; our ability to achieve or sustain profitability; our ability to gain market acceptance for our products and to accurately forecast and meet customer demand; our ability to compete successfully; that data from earlier studies related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings; our ability to enhance our product offerings; product development and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement for procedures using our products; and product defects or failures. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor ContactLouisa Smithir@telabio.com  TELA Bio, Inc.Consolidated Balance Sheets(In thousands, except share and per share amounts)(Unaudited)   December 31,  2024 2023Assets      Current assets:      Cash and cash equivalents $52,670  $46,729 Accounts receivable, net of allowances of $275 and $416  10,098   9,737 Inventory  12,781   13,162 Prepaid expenses and other current assets  2,522   2,098 Total current assets  78,071   71,726 Property and equipment, net  2,341   1,984 Intangible assets, net  1,739   2,119 Right-of-use assets  1,738   1,954 Other long-term assets  2,276   — Deferred tax asset, net  140   — Restricted cash  265   265 Total assets $86,570  $78,048        Liabilities and stockholders’ equity       Current liabilities:      Accounts payable $2,147  $1,667 Accrued expenses and other current liabilities  13,451   15,300 Total current liabilities  15,598   16,967 Long-term debt  41,124   40,515 Other long-term liabilities  1,390   1,685 Total liabilities  58,112   59,167        Stockholders’ equity:      Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding  —   — Common stock; $0.001 par value: 200,000,000 shares authorized; 39,395,712 and 24,494,675 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively  39   24 Additional paid-in capital  387,059   339,655 Accumulated other comprehensive income  90   91 Accumulated deficit  (358,730)  (320,889)Total stockholders’ equity  28,458   18,881 Total liabilities and stockholders’ equity $86,570  $78,048   TELA Bio, Inc.Consolidated Statements of Operations and Comprehensive Loss(In thousands, except share and per share amounts)(Unaudited)   Three Months Ended December 31, Year Ended December 31,  2024 2023 2024 2023Revenue $17,649  $16,998  $69,300  $58,453 Cost of revenue (excluding amortization of intangible assets)  6,333   5,279   22,432   17,961 Amortization of intangible assets  95   95   380   380 Gross profit  11,221   11,624   46,488   40,112 Operating expenses:            Sales and marketing  13,957   17,164   64,648   59,681 General and administrative  3,589   4,053   14,722   14,887 Research and development  2,029   2,685   8,813   9,619 Total operating expenses  19,575   23,902   88,183   84,187 Other operating income:            Gain on sale of product line  —   —   7,580   — Loss from operations  (8,354)  (12,278)  (34,115)  (44,075)Other (expense) income:            Interest expense  (1,283)  (1,345)  (5,290)  (5,223)Other income  285   733   1,420   2,634 Total other expense  (998)  (612)  (3,870)  (2,589)Loss before income tax benefit  (9,352)  (12,890)  (37,985)  (46,664)Income tax benefit  144   —   144   — Net loss $(9,208) $(12,890) $(37,841) $(46,664)Net loss per common share, basic and diluted $(0.23) $(0.53) $(1.33) $(2.04)Weighted average common shares outstanding, basic and diluted  40,074,672   24,490,066   28,526,441   22,868,663 Comprehensive loss:            Net loss $(9,208) $(12,890) $(37,841) $(46,664)Foreign currency translation adjustment  (59)  (44)  (1)  (59)Comprehensive loss $ (9,267) $(12,934) $(37,842) $(46,723)

Related News